The safety labels for the type 2 diabetes drugs Tradjenta (linagliptin tablets) and Jentadueto (linagliptin and metformin) have been updated to include a warning that using the drugs may cause a type of pancreas inflammation known as pancreatitis, which in some cases can be fatal. Tradjenta and Jentadueto, which both include the active ingredient linagliptin, are in a class of oral medications known as dipeptidyl peptidase 4, or DPP-4 inhibitors. Other drugs in this class include Januvia and Onglyza. The warnings state that there have been post-marketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking linagliptin. Doctors who ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.